Two Powerhouses, One Drive: SharkNinja Joins McLaren Racing as Official Partner
15.9.2026 14:00:00 CEST | Business Wire | Press Release
SharkNinja, Inc. (NYSE: SN), a global product design and technology company, is proud to announce its new global partnership with McLaren Racing, the renowned British motorsport team, across its Formula 1, IndyCar, World Endurance Championship, and F1 Academy entries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915026788/en/
As an Official Partner, SharkNinja will become part of the McLaren Racing ecosystem through exclusive experiences, content, and activations designed to connect fans with the ethos and innovation of the two brands. Through the McLaren Racing Accelerator Program, engineers from both companies will work together to apply advanced racing methodologies to the development of future SharkNinja products.
“McLaren is one of the most decorated teams in motorsport history, built on a legacy of innovation, technical excellence, and performance at the highest level," said Mark Barrocas, Chief Executive Officer of SharkNinja. "That is a mindset we share at SharkNinja. We listen closely to consumers, move with speed, and keep iterating until we create solutions that positively impact people’s lives. We are proud to partner with McLaren and combine our strengths to advance innovation for consumers and create unforgettable experiences for fans around the world.”
Highlights of the partnership include:
- McLaren Mastercard Formula 1 Team Experiences: Premium access and brand presence at designated race weekends during the 2026 F1 season, including branded trackside spaces, driver appearances, trophy experiences, and exclusive fan events.
- Driver Partnerships and Performance-Led Storytelling: Exclusive partnerships and content with McLaren Mastercard Formula 1 Team drivers Lando Norris and Oscar Piastri, Formula 1 Legend Mika Häkkinen, up-and-coming F1 Academy female drivers, and McLaren ambassadors, engineers, and leadership, speaking to the shared philosophy behind both brands.
- Multi-Series Expansion: Partnership rights spanning the McLaren Mastercard Formula 1 Team, the Arrow McLaren IndyCar team, the McLaren Hypercar Team competing in the World Endurance Championship, and F1 Academy.
- McLaren Racing Accelerator Program: Leverage McLaren’s world-renowned engineering expertise to inform and elevate SharkNinja’s future product launches, bringing cutting-edge methodologies and performance-driven innovation from the racetrack into consumer products.
“We are delighted to welcome SharkNinja to McLaren Racing,” said Zak Brown, Chief Executive Officer, McLaren Racing. “Innovation and high performance are at the heart of everything we do, and SharkNinja shares our commitment to continually push boundaries through technology and best-in-class customer experiences. We’re excited to work together across our racing series and bring the partnership to life for fans around the world.”
The global partnership will showcase how the same mindset fueling podium finishes also drives breakthrough innovation in everyday life.
About SharkNinja
SharkNinja is a global product design and technology company, with a diversified portfolio of 5-star rated lifestyle solutions that positively impact people’s lives in homes around the world. Powered by two trusted, global brands, Shark and Ninja, the company has a proven track record of bringing disruptive innovation to market and developing one consumer product after another has allowed SharkNinja to enter multiple product categories, driving significant growth and market share gains. Headquartered in Needham, Massachusetts with more than 4,100 associates, the company’s products are sold at key retailers, online and offline, and through distributors around the world. For more information, please visit sharkninja.com.
About McLaren Racing
McLaren Racing was founded by racing driver Bruce McLaren in 1963. The team entered its first Formula 1 race in 1966. McLaren has since won 23 Formula 1 world championships, over 200 Formula 1 Grands Prix, the Indianapolis 500 three times, and the Le Mans 24 Hours at its first attempt.
McLaren Racing competes across four racing series. The team competes in the FIA Formula 1 World Championship with McLaren Mastercard F1 drivers Lando Norris and Oscar Piastri, the NTT INDYCAR SERIES with Arrow McLaren drivers Pato O’Ward, Nolan Siegel and Christian Lundgaard, and F1 Academy with Driver Development Programme members Ella Lloyd and Ella Stevens. The team also competes in the F1 Sim Racing Championship as McLaren Shadow.
McLaren is a champion for sustainability in the sport and a signatory to the UN Sports for Climate Action Commitment. It is committed to achieving net zero by 2040 and fostering a diverse and inclusive culture in the motorsport industry.
McLaren Racing – Official Website
View source version on businesswire.com: https://www.businesswire.com/news/home/20260915026788/en/
Contacts
Investor Relations: ir@sharkninja.com
Public Relations: pr@sharkninja.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo ® ) in Patients With Mycosis Fungoides and Sézary Syndrome12.10.2026 08:00:00 CEST | Press Release
Kyowa Kirin International plc, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides (MF) and Sézary Syndrome (SS). Presented at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) Annual Meeting 2026 in Berlin, Germany, the findings represent one of the largest real-world evaluations of mogamulizumab in Germany and add to the growing body of evidence supporting its use in routine clinical practice.1-3 Conducted as a company-sponsored, multicentric, non-interventional, combined retro-prospective real-world study across 18 centres throughout Germany, MINT brought together cutaneous T‑cell lymphoma (CTCL) specialists to evaluate treatment outcomes with mogamulizumab in a real-world setting, with time-to-next-treatment (TTNT) as the study’s primary endpoint.1 The study captured a broad and heterog
Megaport Expands Global Automated Infrastructure Platform Into Portugal12.10.2026 08:00:00 CEST | Press Release
Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of its services in Portugal, expanding its European footprint and enabling enterprises and service providers in the region to connect instantly to the world’s leading cloud, network, and data center providers. With new on-ramps in Lisbon, customers in Portugal can now access Megaport’s automated infrastructure platform as well as more than 1,200 enabled data centers worldwide. This launch gives enterprises, MSPs, and carriers private, high-performance compute, network, and storage, as well as on-demand regional interconnection with scalable bandwidth. With Portugal’s data center market projected to reach US$3.09 billion by 2030 as well as Lisbon’s proximity to major submarine cable landings, the strengthening global connectivity hub is a natural next step for Megaport. “Portugal’s digital economy is rapidly growing, and infrastructure is at the heart of that transfor
Filippo Fagnani from Quanta System Receives the EAU Award for Significant Contribution to Endourology at ICE 202610.10.2026 18:09:00 CEST | Press Release
Filippo Fagnani, Marketing & Scientific Director of Quanta System’s Surgical Division, has been honoured with the Award for Significant Contribution to Endourology at ICE26, the International Conference on Endourology organised by the EAU Endourology Section. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010101303/en/ Filippo Fagnani receiving the prize with Olivier Traxer and Professor Bhaskar Somani. The recognition celebrates more than two decades of professional commitment to laser technology and a career built around a clear ambition: to translate the needs of urologists into increasingly precise, flexible and useful technologies, with the ultimate goal of supporting patient safety and better surgical outcomes. “I have always believed that technology should make the surgeon’s work more precise, more flexible and, most importantly, safer for the patient. My goal has never been to develop technology for its own sake,
Emdoor Information Marks 18 Years of Rugged Computing Excellence with Vertically Integrated Capabilities10.10.2026 12:30:00 CEST | Press Release
As industrial automation, smart manufacturing, and field operations increasingly depend on mission-critical mobile computing, global demand for reliable rugged tablets, rugged laptops, and rugged handhelds continues to accelerate. Emdoor Information, a publicly listed company on China’s A-share main board since 2023 and an 18-year veteran in rugged computing, has established itself as a rugged computing solutions provider for industrial customers worldwide. Founded in 2008, the company delivers sustained growth, world-class manufacturing, resilient supply chains, full-stack R&D, and comprehensive lifecycle services. Its rugged computing products and industrial customers now span North America, Latin America, Europe, and Asia-Pacific, serving sectors such as public utilities, intelligent manufacturing, warehouse management, transportation, energy industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010564561/en/ Rugged
Vertex to Present New Data on ALYFTREK ® at the North American Cystic Fibrosis Conference9.10.2026 19:15:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine pancreatic function represent a profound shift in how we understand the benefits of treating cystic fibrosis in its earliest stages,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Devel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom